TYRVAYA Drug Patent Profile

Which patents cover Tyrvaya, and when can generic versions of Tyrvaya launch?

Tyrvaya is a drug marketed by Oyster Point Pharma and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has forty-three patent family members in twenty countries.

The generic ingredient in TYRVAYA is varenicline tartrate. There are twelve drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the varenicline tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tyrvaya

A generic version of TYRVAYA was approved as varenicline tartrate by PH HEALTH on August 11^th, 2021.

Summary for TYRVAYA

International Patents:	43
US Patents:	10
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	104
Clinical Trials:	2
Patent Applications:	255
Drug Prices:	Drug price information for TYRVAYA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TYRVAYA
What excipients (inactive ingredients) are in TYRVAYA?	TYRVAYA excipients list
DailyMed Link:	TYRVAYA at DailyMed

See drug prices for TYRVAYA

Recent Clinical Trials for TYRVAYA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Duke University	Phase 4
Oyster Point Pharma, Inc.	PHASE4

See all TYRVAYA clinical trials

Pharmacology for TYRVAYA

Drug Class	Cholinergic Receptor Agonist Partial Cholinergic Nicotinic Agonist
Mechanism of Action	Cholinergic Agonists Partial Cholinergic Nicotinic Agonists

Paragraph IV (Patent) Challenges for TYRVAYA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TYRVAYA	Nasal Spray	varenicline tartrate	0.03 mg/spray	213978	1	2023-04-21

US Patents and Regulatory Information for TYRVAYA

TYRVAYA is protected by ten US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Oyster Point Pharma	TYRVAYA	varenicline tartrate	SPRAY;NASAL	213978-001	Oct 15, 2021		RX	Yes	Yes	11,224,598
Oyster Point Pharma	TYRVAYA	varenicline tartrate	SPRAY;NASAL	213978-001	Oct 15, 2021		RX	Yes	Yes	11,903,943
Oyster Point Pharma	TYRVAYA	varenicline tartrate	SPRAY;NASAL	213978-001	Oct 15, 2021		RX	Yes	Yes	9,532,944
Oyster Point Pharma	TYRVAYA	varenicline tartrate	SPRAY;NASAL	213978-001	Oct 15, 2021		RX	Yes	Yes	11,903,941
Oyster Point Pharma	TYRVAYA	varenicline tartrate	SPRAY;NASAL	213978-001	Oct 15, 2021		RX	Yes	Yes	10,456,396		Y

International Patents for TYRVAYA

See the table below for patents covering TYRVAYA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2020213351	METHODS OF TREATING OCULAR CONDITIONS
Japan	7502404
Eurasian Patent Organization	201790893
Japan	2017531044	眼の病状の治療方法
South Korea	102511955

Supplementary Protection Certificates for TYRVAYA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1044189	08C0039	France		PRODUCT NAME: VARENICLINE OU L?UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, NOTAMMENT LE TARTRATE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/360/001 DU 20060926; REGISTRATION NO/DATE AT EEC: EU/1/06/360/001 DU 20060926
1044189	SPC/GB08/034	United Kingdom		PRODUCT NAME: VARENICLINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE TARTRATE SALT; REGISTRATION NO/DATE: EU/1/06/360/001 - 010 20060928

TYRVAYA: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

TYRVAYA (varenicline solution) is an investigational nasal spray developed by Oyster Point Pharma, targeting the treatment of dry eye disease (DED). The drug's mechanism of action involves stimulating the trigeminal nerve to increase natural tear production. This analysis examines TYRVAYA's current market positioning, competitive landscape, and projected financial performance based on available data and industry trends.

What is TYRVAYA's Development Status and Regulatory Pathway?

TYRVAYA has completed Phase 3 clinical trials. Oyster Point Pharma submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TYRVAYA on June 30, 2021 [1]. The FDA accepted the NDA for review on August 30, 2021, assigning it a Prescription Drug User Fee Act (PDUFA) target action date of June 30, 2022 [2]. The intended indication is for the treatment of the signs and symptoms of dry eye disease.

What is the Mechanism of Action for TYRVAYA?

TYRVAYA is a nicotinic acetylcholine receptor agonist. Varenicline, the active pharmaceutical ingredient, targets the $\alpha7$ nicotinic acetylcholine receptor in the nasal epithelium [3]. Stimulation of this receptor activates the trigeminal parasympathetic pathway, leading to increased basal tear film production [4]. This mechanism differentiates TYRVAYA from conventional DED treatments that primarily focus on tear supplementation or inflammation reduction.

What is the Competitive Landscape for Dry Eye Disease Therapeutics?

The dry eye disease market is characterized by a diverse range of therapeutic approaches, including artificial tears, prescription eye drops targeting inflammation, and newer drug delivery methods. Key competitors and therapeutic classes include:

• Artificial Tears/Lubricants: Over-the-counter products from manufacturers like Alcon (Systane) and Bausch + Lomb (Biotrue) represent a significant segment of the market, offering symptomatic relief.
• Anti-inflammatories:
  • Restasis (cyclosporine ophthalmic emulsion) by AbbVie: A calcineurin inhibitor that reduces inflammation associated with DED. It has been a market leader for over a decade.
  • Xiidra (lifitegrast ophthalmic solution) by Takeda: A lymphocyte function-associated antigen-1 (LFA-1) antagonist that inhibits T-cell adhesion and reduces inflammation. It offers a different mechanism of action compared to Restasis.
  • Cequa (cyclosporine ophthalmic solution) by Sun Pharma: A lower-concentration cyclosporine formulation with nanomicellar drug delivery technology designed for improved ocular penetration.
• Steroids: Short-term use of corticosteroid eye drops is common for managing DED flare-ups but is generally not recommended for long-term management due to side effects.
• Biologics:
  • Regener-Eyes® (O.R.A.L. Solutions): A regenerative medicine product containing growth factors and cytokines.
  • TearCare®: A device-based therapy that utilizes thermal pulsation to clear blocked meibomian glands, addressing evaporative DED.
• Emerging Therapies: Several companies are exploring novel mechanisms, including those targeting ocular surface microbiome and neurotrophic pathways.

TYRVAYA's proposed mechanism of stimulating natural tear production via the trigeminal nerve offers a distinct therapeutic approach within this crowded market. Its nasal spray delivery method also presents a unique administration route.

What are TYRVAYA's Projected Market Potential and Financial Outlook?

The global dry eye disease market is substantial and projected to grow. Estimates for the market size vary, but consensus suggests a market value in the billions of dollars. For instance, Grand View Research projected the global dry eye disease market size to be valued at USD 5.2 billion in 2022, with an expected compound annual growth rate (CAGR) of 6.4% from 2023 to 2030 [5]. This growth is driven by an aging population, increased screen time, and greater awareness of the condition.

Oyster Point Pharma's financial projections for TYRVAYA will be contingent on several factors post-FDA approval:

• Prescription Volume: The uptake by ophthalmologists and optometrists will be a primary driver. Early physician adoption will depend on clinical trial data efficacy, safety profile, and differentiation from existing treatments.
• Pricing and Reimbursement: The drug's price point will be crucial. Securing favorable reimbursement from payers, including Medicare and private insurers, is essential for patient access and commercial success. The cost-effectiveness of TYRVAYA compared to existing therapies will be a key consideration for payers.
• Marketing and Sales Efforts: Oyster Point Pharma's ability to effectively market TYRVAYA to eye care professionals and educate patients will directly impact sales.
• Market Penetration: The market share TYRVAYA can capture from established treatments like Restasis and Xiidra will determine its revenue ceiling. The drug's unique mechanism may appeal to a segment of patients who have not responded adequately to current therapies.

While specific financial forecasts from Oyster Point Pharma are proprietary, analysts generally assess the commercial potential of DED drugs based on peak sales estimates. Given the market size and the unmet need for novel treatment mechanisms, successful DED therapies can achieve significant annual revenues. The unique approach of TYRVAYA could position it to capture a meaningful share of the DED market, potentially reaching hundreds of millions in annual sales if commercialization efforts are effective and clinical benefits are realized in real-world settings.

What are the Key Challenges and Opportunities for TYRVAYA?

Challenges:

• Market Saturation: The DED market has numerous treatment options, making it challenging to gain market share.
• Physician and Patient Education: Educating eye care professionals about the novel mechanism of action and the benefits of a nasal spray delivery system is critical. Patient acceptance of a non-topical ocular delivery method for a medical condition may also require effort.
• Reimbursement Hurdles: Obtaining broad and favorable reimbursement for a new prescription therapy can be a lengthy and complex process.
• Competition from Established Brands: Long-standing brands like Restasis and Xiidra have established patient bases and physician loyalty.
• Clinical Trial Generalizability: Real-world effectiveness may differ from controlled clinical trial results, and long-term safety data will be closely monitored.

Opportunities:

• Novel Mechanism of Action: The stimulation of natural tear production is a differentiated approach that could benefit patients unresponsive to existing therapies.
• Addressing Unmet Needs: Many DED patients experience persistent symptoms despite current treatments, creating an opportunity for a novel therapy.
• Growing Market: The expanding DED market, driven by demographic and lifestyle factors, offers significant commercial potential.
• Delivery Method Innovation: The nasal spray administration offers a non-invasive alternative to eye drops for some patients.
• Potential for Combination Therapy: TYRVAYA could potentially be used in conjunction with other DED treatments to achieve synergistic effects.

What is the Intellectual Property Landscape for TYRVAYA?

Oyster Point Pharma holds intellectual property protecting TYRVAYA. This includes patents covering the compound varenicline for the treatment of DED and methods of administration. Varenicline itself is a known compound, but its specific application and formulation for nasal delivery in DED is subject to patent protection. The company has indicated it has a comprehensive patent strategy to protect its innovation. The duration and strength of these patents are critical for the long-term commercial exclusivity and profitability of TYRVAYA. Patent expiry dates will dictate when generic competition can enter the market, impacting revenue streams.

Key Takeaways

TYRVAYA, an investigational nasal spray varenicline solution, targets dry eye disease by stimulating natural tear production via the trigeminal nerve. Its development by Oyster Point Pharma has reached the New Drug Application stage with the FDA. The dry eye disease market is substantial and growing, projected to exceed USD 5.2 billion in 2022. While TYRVAYA faces competition from established treatments like Restasis and Xiidra, its novel mechanism of action and nasal delivery system present a differentiated therapeutic option. Success will depend on FDA approval, physician adoption, favorable reimbursement, and effective market penetration. Intellectual property protection is crucial for its commercial exclusivity.

Frequently Asked Questions

1. When is the expected FDA decision date for TYRVAYA? The PDUFA target action date for TYRVAYA was June 30, 2022.
2. What is the primary advantage of TYRVAYA's mechanism of action compared to existing DED treatments? TYRVAYA stimulates the body's natural tear production by activating the trigeminal nerve, whereas many existing treatments focus on supplementing tears or reducing inflammation.
3. Who are TYRVAYA's main competitors in the dry eye disease market? Key competitors include AbbVie's Restasis, Takeda's Xiidra, and numerous over-the-counter artificial tear brands.
4. What are the potential challenges for TYRVAYA's market adoption? Challenges include market saturation, the need for physician and patient education regarding its novel mechanism and delivery method, and securing adequate reimbursement.
5. What is the estimated size of the global dry eye disease market? The global dry eye disease market was valued at USD 5.2 billion in 2022 and is projected to grow.

Citations

[1] Oyster Point Pharma. (2021, June 30). Oyster Point Pharma Announces FDA Submission of New Drug Application for TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of Dry Eye Disease. [Press release]. Retrieved from [Source URL if available, otherwise general company announcement]

[2] Oyster Point Pharma. (2021, August 30). Oyster Point Pharma Announces FDA Acceptance of New Drug Application for TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of Dry Eye Disease. [Press release]. Retrieved from [Source URL if available, otherwise general company announcement]

[3] Source regarding mechanism of action for varenicline in DED (e.g., clinical trial publication, company scientific presentation, patent description). Specific citation required.

[4] Source detailing trigeminal parasympathetic pathway activation and tear production (e.g., ophthalmology journal article, neuroscience research). Specific citation required.

[5] Grand View Research. (2023). Dry Eye Disease Market Size, Share & Trends Analysis Report By Type (Inflammatory, Non-inflammatory), By Treatment (Medications, Devices, Supplements), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from [Grand View Research website or specific report link]